Puma Biotechnology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Puma Biotechnology, Inc.
In a rare disease indication, clinical trial efficacy in Phase III should be the ticket to successful sales. But safety issues warrant careful consideration.
Public Company Edition: This year is just six initial public offerings away from matching 2020’s record-breaking total of 86 biopharma IPOs in the US. Also, Idorsia raised $662.5m through the sale of convertible bonds and Cytokinetics closed a $316.3m follow-on offering.
The Beijing/Boston-based bioventure shocked the industry with its recent announcement of the return of exclusive rights to an oncology assets in the greater China area to its US licensee, in an effort to focus squarely on rare diseases. CEO James Xue shares his views on this market in China in an exclusive interview with Scrip.
The drug may see a muted launch given the competitive landscape and a broad label despite its efficacy advantage in F-allele patients.
- Specialty Pharmaceuticals